“FOR THE VERY FIRST TIME IN HUMAN HISTORY, BIOLOGY HAS THE OPPORTUNITY TO BE ENGINEERING — NOT SCIENCE”
As the visionary behind NVIDIA, Jensen Huang has not only revolutionized computing, gaming, and artificial intelligence—he’s now shaping the future of biology. Under his leadership, NVIDIA has grown into a $2 trillion powerhouse and emerged as a critical enabler of a new paradigm: biology as an engineerable, programmable system.
Huang sees biology as nature’s most powerful computing platform—and believes that with enough computational power, we can simulate, understand, and ultimately program it. That belief is now materializing through NVIDIA’s bold forays into the life sciences.
Among Huang’s most transformative initiatives is the launch of BioNeMo Cloud, a platform built specifically to develop and deploy large-scale foundation models for proteins, DNA, RNA, and small molecules. With BioNeMo, researchers and startups can now tap into pretrained generative models to design novel compounds, predict protein structures, or simulate biological behavior—tasks that were once reserved for years of wet-lab work.
NVIDIA’s strategy goes beyond infrastructure. Under Huang’s leadership, the company has actively invested in and partnered with key players in BioPharma, signaling a long-term commitment to this space. In 2023, NVIDIA made a $50 million investment in Recursion, one of the world’s leading AI-native biotech companies. The partnership combines Recursion’s massive phenomics datasets and lab automation with NVIDIA’s compute platform—accelerating drug discovery at scale.
Huang has also forged deep collaborations with BioPharma leaders like Amgen, Genentech, and Evozyne, helping them integrate AI into protein engineering, antibody discovery, and molecular design. These partnerships reflect a shared vision: to bring the precision and scalability of computation into the traditionally slow, complex world of biology.
One of the most ambitious examples of this vision is the supercomputer developed by the Novo Nordisk Foundation, built using NVIDIA’s DGX platform. Designed specifically to accelerate AI-driven drug discovery, this system enables Novo Nordisk to simulate, optimize, and predict molecular interactions at a previously unthinkable scale. By running deep learning models on massive datasets—including omics, chemical structures, and real-world clinical data—Novo Nordisk aims to cut down the time from target discovery to clinical trial readiness. This represents a critical leap forward in therapeutic development for complex diseases like diabetes, obesity, and cardiometabolic disorders.
At the foundation of this ecosystem lies NVIDIA hardware and compute platforms powering some of the most advanced biological models in use today: AlphaFold, which predicts protein structures with remarkable accuracy; RoseTTAFold, which extends deep learning into multi-domain folding; and BioGPT, which models biological language for knowledge extraction and hypothesis generation.
This is more than digital transformation—it’s the birth of a programmable bioeconomy, where the design-build-test cycle of biology begins to mirror the speed and repeatability of software engineering. In this future, diseases are not just treated—they are modeled, predicted, and increasingly engineered out of existence.
By merging the worlds of silicon and biology, Huang is catalyzing a new era of compounding innovation—not just in code, but in cells.